- Home
- SIGI vs APLS Comparison
SIGI vs APLS Comparison
Compare SIGI & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SIGI | APLS |
|---|---|---|
| Founded | 1926 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.2B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SIGI | APLS |
|---|---|---|
| Price | $82.12 | $40.96 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 21 |
| Target Price | ★ $85.80 | $33.59 |
| AVG Volume (30 Days) | 523.3K | ★ 3.8M |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $0.41 | N/A |
| Revenue Next Year | $4.81 | $18.19 |
| P/E Ratio | ★ $11.38 | $204.78 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $71.75 | $16.10 |
| 52 Week High | $91.63 | $41.00 |
Technical Indicators
Market Signals| Indicator | SIGI | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 86.68 |
| Support Level | $81.72 | $19.29 |
| Resistance Level | $86.18 | $40.98 |
| Average True Range (ATR) | 2.74 | 0.06 |
| MACD | -0.08 | -0.75 |
| Stochastic Oscillator | 51.92 | 82.50 |
Price Performance
Historical ComparisonAbout SIGI Selective Insurance Group Inc.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, and Investments. Majority of revenue is gained from Standard Commercial Lines segment, which comprises of property and casualty insurance products and services provided in the standard marketplace to commercial enterprises, which are typically businesses, non-profit organizations, and local government agencies.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).